A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the maximum tolerated dose (MTD) of SCB-313.
Malignant Pleural Effusion
DRUG: SCB-313
DLT, Dose Limiting Toxicity, 28 days after first dosing
AEs, Occurrence of adverse events (AEs) and serious adverse events (SAEs), 28 days after first dosing|Immunogenicity, Occurrence of binding and neutralizing anti-SCB-313 antibodies, up to 28 days after first dosing
To evaluate the safety and tolerability of single dose of SCB-313 by intrapleural injection.To evaluate the safety and tolerability of repeated dose of SCB-313 by intrapleural injection once a day for 3 days, and to determine the maximum tolerated dose (MTD) of SCB-313.